



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/300785/2015

European Medicines Agency decision

P/0118/2015

of 5 June 2015

on the acceptance of a modification of an agreed paediatric investigation plan for artemether / lumefantrine (Riamet), (EMEA-000777-PIP01-09-M05) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0118/2015

of 5 June 2015

on the acceptance of a modification of an agreed paediatric investigation plan for artemether / lumefantrine (Riamet), (EMA-000777-PIP01-09-M05) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/177/2010 issued on 21 September 2010, the decision P/205/2011 issued on 26 August 2011, the decision P/0075/2012 issued on 25 April 2012, and the decision P/0285/2012 issued on 23 November 2012,

Having regard to the application submitted by Novartis Europharm Limited on 23 January 2015 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 17 April 2015, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the waiver.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for artemether / lumefantrine (Riamet), tablet, dispersible tablet, oral use, including changes to the waiver, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Novartis Europharm Limited, Wimblehurst Road Horsham, RH125 AB - West Sussex, United Kingdom.

Done at London, 5 June 2015

For the European Medicines Agency
Jordi Llinares Garcia
Head of Division (ad interim)
Human Medicines Research and Development Support
(Signature on file)



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/72182/2015
London, 17 April 2015

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-000777-PIP01-09-M05

Scope of the application

Active substance(s):

Artemether / lumefantrine

Invented name:

Riamet

Condition(s):

Treatment of *Plasmodium falciparum* malaria

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Tablet

Dispersible tablet

Route(s) of administration:

Oral use

Name / corporate name of the PIP applicant:

Novartis Europharm Limited

Information about the authorised medicinal product:

See Annex II



Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Novartis Europharm Limited submitted to the European Medicines Agency on 23 January 2015 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/177/2010 issued on 21 September 2010, the decision P/205/2011 issued on 26 August 2011, the decision P/0075/2012 issued on 25 April 2012, and the decision P/0285/2012 issued on 23 November 2012.

The application for modification proposed changes to the agreed paediatric investigation plan and to the waiver.

The procedure started on 17 February 2015.

Scope of the modification

Some measures of the Paediatric Investigation Plan have been modified. A waiver for a new paediatric subset has been added.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree to changes to the paediatric investigation plan and to the waiver in the scope set out in the Annex I of this opinion.

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Treatment of *Plasmodium falciparum* malaria

The waiver applies to:

- paediatric population below 5 kg bodyweight;
- for artemether / lumefantrine tablet, oral use;
- on the grounds that the specific medicinal product in this pharmaceutical form is likely to be unsafe.

The waiver applies to:

- paediatric population from 5 kg bodyweight and above;
- for artemether / lumefantrine tablet, oral use;
- on the grounds that clinical studies cannot be expected to be of significant therapeutic benefit as the needs are already covered.

The waiver applies to:

- newborn infants (from birth to less than 28 days and below 5 kg bodyweight);
- for artemether / lumefantrine dispersible tablet, oral use;
- on the grounds that the specific medicinal product is likely to be unsafe.

The waiver applies to:

- children and adolescents weighing 35 kg or more;
- for artemether / lumefantrine dispersible tablet, oral use;
- on the grounds that clinical studies cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the paediatric population.

2. Paediatric Investigation Plan

2.1. Condition

Treatment of *Plasmodium falciparum* malaria

2.1.1. Indication(s) targeted by the PIP

Treatment of acute uncomplicated *Plasmodium falciparum* malaria

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

Paediatric population less than 35 kg, except newborn infants less than 28 days and below 5 kg body weight

2.1.3. Pharmaceutical form(s)

Dispersible tablet (20 mg artemether / 120 mg lumefantrine)

2.1.4. Studies

Area	Number of studies	Description
Quality-related studies	1	Study 1 Development of dispersible tablet for oral use.
Non-clinical studies	2	Study 2 Juvenile development dose-ranging finding study of oral artemether in rats. Study 3 Juvenile development study in rats of artemether.
Clinical studies	2	Study 4 Randomised, investigator-blinded, multicentre, parallel-group trial to compare the efficacy, safety and tolerability of the artemether / lumefantrine dispersible tablet versus the artemether/lumefantrine tablet administered crushed in the treatment of acute uncomplicated <i>Plasmodium falciparum</i> malaria in infants and children from 5 kg to less than 35 kg body weight. Study 5 Open-label, single arm, multicentre trial to evaluate the pharmacokinetics, efficacy and safety of artemether/lumefantrine dispersible tablet in the treatment of acute uncomplicated <i>Plasmodium falciparum</i> malaria in neonates and infants who weigh less than 5 kg.
Extrapolation, modelling and simulation studies	0	Not applicable.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2014
Deferral for one or more studies contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s)

1. Treatment of *Plasmodium falciparum* malaria

Authorised indication(s):

- Riamet is indicated for the treatment of acute uncomplicated *Plasmodium falciparum* malaria in adult, children and infants of 5 kg and above.

Consideration should be given to official guidance regarding the appropriate use of antimalarial agents.

Authorised pharmaceutical form(s)

Tablets

Dispersible tablets

Authorised route(s) of administration

Oral use